A Phase I/IIa, Dose-escalation and Dose-expansion Study to Evaluate the Safety and Efficacy of Single Subretinal Injection of RRG001 in Subjects With Neovascular Age-related Macular Degeneration
Subjects that are willing and able to follow study procedures.
Patinets ≥50 years old.
Clinically diagnosed with CNV secondary to nAMD.
BCVA of the study eye is ≥5 letters and ≤73 letters(Snellen 20/800~20/40), as well as that of the other eye ≥19 letters(Snellen 20/400).
Presence of any other eye diseases other than nAMD in study eye that would affect the treatment or confusing the interpretation of the study results , as judged by the investigator.
CNV or macular edema in the study eye secondary to any causes other than AMD.
Uncontrolled glaucoma.
Uncontrolled hypertension despite medication.